Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cellectis SA ( (CLLS) ) has provided an announcement.
On October 16, 2025, Cellectis S.A. hosted an Investors R&D Day, unveiling promising data from the Phase 1 BALLI-01 study of lasme-cel (UCART22) for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study showed lasme-cel was generally well-tolerated and demonstrated significant efficacy, with a 68% overall response rate and 83% achieving minimal residual disease-negative status in the target Phase 2 population. The company announced the initiation of the pivotal Phase 2 trial and outlined a registration path for lasme-cel as a bridge to transplant in r/r ALL, with a Biologics License Application submission anticipated in 2028. This development positions lasme-cel as a potential game-changer in the industry, offering a new treatment option for heavily pretreated patients and potentially capturing a significant share of the market.
The most recent analyst rating on (CLLS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is driven by positive technical momentum and encouraging earnings call sentiment, particularly regarding clinical trial progress and strategic partnerships. However, financial performance challenges and valuation uncertainties due to ongoing losses weigh on the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company that utilizes its pioneering gene editing platform to develop life-saving cell and gene therapies. The company focuses on creating allogeneic CAR-T therapies, which are designed to be safer, faster, and more scalable and accessible, aiming to address significant unmet needs in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Average Trading Volume: 192,875
Technical Sentiment Signal: Buy
Current Market Cap: $342.9M
For detailed information about CLLS stock, go to TipRanks’ Stock Analysis page.